[go: up one dir, main page]

WO1992005266A3 - Cellules d'encapsidation - Google Patents

Cellules d'encapsidation Download PDF

Info

Publication number
WO1992005266A3
WO1992005266A3 PCT/US1991/006852 US9106852W WO9205266A3 WO 1992005266 A3 WO1992005266 A3 WO 1992005266A3 US 9106852 W US9106852 W US 9106852W WO 9205266 A3 WO9205266 A3 WO 9205266A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
retrovirus
recombinant
particular cell
cell type
Prior art date
Application number
PCT/US1991/006852
Other languages
English (en)
Other versions
WO1992005266A2 (fr
Inventor
Douglas J Jolly
Jack R Barber
James G Respess
Stephen M W Chang
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to AU88424/91A priority Critical patent/AU665176B2/en
Priority to CA002092195A priority patent/CA2092195C/fr
Publication of WO1992005266A2 publication Critical patent/WO1992005266A2/fr
Publication of WO1992005266A3 publication Critical patent/WO1992005266A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/30—Rearing or breeding invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention permet la production de rétrovirus recombinés (particules vectorielles rétrovirales) à partir de cellules productrices plus sûres et d'un titre supérieur à la normale. De plus, l'invention concerne des procédés de production de cellules auxiliaires qui, lorsqu'un génome de rétrovirus recombiné est introduit afin de produire une lignée productrice, produisent des particules dont les cibles sont des types particuliers de cellules. De plus, l'invention concerne des procédés de production de systèmes de rétrovirus recombinés adaptés pour infecter un type particulier de cellules, tel qu'une tumeur, par liaison du rétrovirus ou du rétrovirus recombiné dans le type particulier de cellules. En outre, l'invention concerne des procédés de production de rétrovirus recombinés s'intégrant dans un petit nombre spécifique d'endroits dans le génome hôte, et des procédés de production de rétrovirus recombinés à partir d'animaux transgéniques.
PCT/US1991/006852 1990-09-21 1991-09-20 Cellules d'encapsidation WO1992005266A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU88424/91A AU665176B2 (en) 1990-09-21 1991-09-20 Packaging cells
CA002092195A CA2092195C (fr) 1990-09-21 1991-09-20 Lignee cellulaire a encapsidation retrovirale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58660390A 1990-09-21 1990-09-21
US586,603 1990-09-21

Publications (2)

Publication Number Publication Date
WO1992005266A2 WO1992005266A2 (fr) 1992-04-02
WO1992005266A3 true WO1992005266A3 (fr) 1992-07-23

Family

ID=24346413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006852 WO1992005266A2 (fr) 1990-09-21 1991-09-20 Cellules d'encapsidation

Country Status (5)

Country Link
EP (3) EP0549723A1 (fr)
JP (3) JPH06500923A (fr)
AU (2) AU665176B2 (fr)
CA (1) CA2092195C (fr)
WO (1) WO1992005266A2 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993020221A1 (fr) * 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
WO1993022433A2 (fr) * 1992-04-28 1993-11-11 Frank Andreas Harald Meyer Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
AU688292B2 (en) * 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
JP3866760B2 (ja) * 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
JPH08507687A (ja) 1993-03-12 1996-08-20 クレイトン ユニバーシティ 遺伝子治療用の改良されたベクター
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2716461A1 (fr) * 1994-02-22 1995-08-25 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
AU2648295A (en) * 1994-06-07 1996-01-04 Immunomedics Inc. Safe retroviral vectors, their production and use
JPH10507905A (ja) * 1994-08-17 1998-08-04 ジェネティック セラピー インコーポレイテッド ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
CA2202408C (fr) * 1994-10-20 2012-03-06 Pierre Charneau Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
FR2727429B1 (fr) 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
EP0877752B1 (fr) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Procedes servant a rechercher par criblage des peptides effecteurs et des molecules d'arn transdominants
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
WO1997042338A1 (fr) * 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2317815A1 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1953229A3 (fr) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Gênes régulés du cancer du sein et du colôn métastatiques
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1141331B1 (fr) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. KINASE DEPENDANT DE LA CYCLINE DE TYPE HUMAIN (hPNQALRE)
AU4012900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Methods for producing a vector producing cell line utilizing a high multiplicityof transduction
ES2397918T3 (es) 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
MXPA02004283A (es) 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
NZ521396A (en) 2000-02-28 2004-06-25 Chiron S Fusion proteins comprising two or more Neisseria polypeptides
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
WO2001068828A2 (fr) 2000-03-13 2001-09-20 Engene, Inc. Compositions et methodes destinees a l'expression regulee d'une proteine dans l'intestin
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (fr) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2344208A1 (fr) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Methode
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
ES2411981T3 (es) 2002-02-01 2013-07-09 Oxford Biomedica (Uk) Limited Vector lentivírico
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
CA2572467A1 (fr) * 2004-07-01 2006-01-19 Virxsys Corporation Lignee cellulaire d'encapsidation de vecteurs
CA2524619A1 (fr) 2005-11-22 2007-05-22 Ottawa Health Research Institute Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
KR20140102327A (ko) 2007-02-06 2014-08-21 유태준 유전자 요법을 사용한 신경퇴행성 질환의 치료 및 예방
WO2008116116A2 (fr) 2007-03-20 2008-09-25 Harold Brem Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
WO2009058451A2 (fr) 2007-08-02 2009-05-07 California Stem Cell, Inc. Cellules progénitrices neuronales et procédés de dérivation et de purification de cellules progénitrices neuronales de cellules souches embryonnaires
ES2662030T3 (es) 2007-10-15 2018-04-05 Admedus Vaccines Pty Limited Sistema de construcciones y usos para el mismo
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
PL2252317T3 (pl) 2008-02-15 2014-09-30 Univ Tufts Leczenie zwyrodnienia plamki żółtej
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US8211487B2 (en) 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
AU2010242598C1 (en) 2009-04-27 2015-02-05 Kyowa Kirin Co., Ltd. Anti-IL-3Ralpha antibody for use in treatment of blood tumor
JP5923037B2 (ja) 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
WO2011060233A1 (fr) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anticorps anti-tem1 et leurs utilisations
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012021891A2 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, kits et méthodes de traitement de pathologies associées au complément
EP2663868A2 (fr) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Procédés et compositions destinés à cibler des sites de croissance néovasculaire
WO2013040517A2 (fr) 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Immunothérapie et diagnostic de la mucormycose au moyen de coth
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2014197599A1 (fr) 2013-06-04 2014-12-11 The Johns Hopkins University Expression en surface de l'avidine/streptavidine, médiée par peg-prom
US10166300B2 (en) 2013-06-04 2019-01-01 Virginia Commonwealth University Tripartite cancer theranostic nucleic acid constructs
EP3004153B1 (fr) 2013-06-04 2019-10-30 Virginia Commonwealth University Cytokines thérapeutiques recombinantes contre le cancer
WO2014209553A1 (fr) 2013-06-04 2014-12-31 Virginia Commonwealth University Utilisation d'un promoteur de ccn1 tronqué pour le diagnostic, la thérapeutique et la théragnostique de cancer
EP3004872B1 (fr) 2013-06-04 2017-10-18 Virginia Commonwealth University Promoteur du gène de la synténine (mda-9) utilisé pour la prise d'image et le traitement de cellules cancéreuses métastatiques
EP3013945B1 (fr) 2013-06-25 2020-05-27 Temple University Of The Commonwealth System Of Higher Education Cellules souches dérivées d'os cortical
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
WO2015148683A1 (fr) 2014-03-26 2015-10-01 Tocagen Inc. Vecteur rétroviral à activité de stimulation immunitaire
AU2015308773B2 (en) 2014-08-28 2021-03-25 Tufts University Compositions, methods and kits for treating complement related disorders
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP7110108B2 (ja) 2015-12-09 2022-08-01 ジンガン メディスン（オーストラリア） プロプライアタリー リミティド 治療用免疫調節組成物
GB201603372D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Cell
AU2017250191A1 (en) 2016-04-13 2018-11-08 Orimabs Ltd. Anti-PSMA antibodies and use thereof
EP3299460A1 (fr) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composes et procedes destines a moduler l'expression de l'ubiquitination
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
MX2020008457A (es) 2018-02-12 2020-12-07 Tufts College Cd59 para inhibir la activacion del inflamasoma.
US12233135B2 (en) 2018-04-11 2025-02-25 Precision Molecular Inc. Therapeutic constructs for treating cancer
EP3897706A4 (fr) 2018-12-21 2022-11-23 Griffith University Compositions, méthodes et utilisations pour provoquer une réponse immunitaire
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (fr) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Polypeptides se liant à cd33 avec protéine stefin a
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
KR20240107156A (ko) 2021-11-19 2024-07-08 얀센 바이오테크 인코포레이티드 가용성 cd59를 발현하는 유전자 요법 벡터를 이용한 지도형 위축의 치료 방법
WO2023212483A1 (fr) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Méthodes et compositions pour le traitement de maladies et de troubles à éosinophiles
WO2025074268A1 (fr) 2023-10-02 2025-04-10 Janssen Biotech, Inc. Méthodes pour traiter la dégénérescence maculaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651311B2 (en) * 1988-03-21 1994-07-21 Chiron Corporation Recombinant retroviruses
WO1991019803A1 (fr) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, vol. 64, no. 3, March 1990, F.-L. COSSET et al.: "A new avian leukosis virus-based packaging cell line that uses two separate transcomplementing helper genomes", pages 1070-1078, see the whole document, specially page 1076, column 2 *
Nucleic Acids Research, vol. 18, no. 12, 25 June 1990, J.P. MORGENSTERN et al.: "Advanced mammalian gene tranfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line", pages 3587-3596, see the whole document *

Also Published As

Publication number Publication date
JPH06500923A (ja) 1994-01-27
JP4092278B2 (ja) 2008-05-28
EP0854193A1 (fr) 1998-07-22
CA2092195C (fr) 2000-04-18
EP1285967A2 (fr) 2003-02-26
AU690427B2 (en) 1998-04-23
AU665176B2 (en) 1995-12-21
JP2004041234A (ja) 2004-02-12
AU4798496A (en) 1996-06-20
WO1992005266A2 (fr) 1992-04-02
CA2092195A1 (fr) 1992-03-22
EP1285967A3 (fr) 2005-03-02
EP0549723A1 (fr) 1993-07-07
JP2003159062A (ja) 2003-06-03
AU8842491A (en) 1992-04-15

Similar Documents

Publication Publication Date Title
WO1992005266A3 (fr) Cellules d'encapsidation
GB2325003A (en) Rectroviral vectors
CA2328404A1 (fr) Nouvelles cellules lentivirales d'encapsidation
IL204703A0 (en) Immunogenic composition comprising recombinat vector, recombinat cell, transduced with the recombinat vector and a vector
CA2074355A1 (fr) Plants de mais transgeniques fertiles
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
WO1996037623B1 (fr) Vecteurs retroviraux
WO2000017365A8 (fr) Systeme binaire d'expression virale dans des plantes
CA2130454A1 (fr) Production de plantes viro-resistantes par l'introduction d'arn viral sens non traduisible
HUP9801855A2 (hu) Növényekben szintetizált és azokból kinyert módosított keményítő, valamint eljárás előállításukra
GB2331522A (en) Lentiviral vectors
NO163620C (no) Ethylenpolymerer inneholdende enheter avledet fra maleinsyreanhydrid, fremgangsmaate for fremstilling av pylymerene og deres anvendelse for fremstilling av folier.
NO975813D0 (no) Innkapslede celler som produserer virale partikler
HU9200260D0 (en) Plazmide-producing process for producing posttransformed retrovirus gene, plazmide from them and products from them
WO2001005936A3 (fr) Methode de transformation et plantes transgeniques ainsi produites
WO1996007749A3 (fr) Procedes et compositions d'inhibition de la production de virus aptes a la replication
JPH10507628A (ja) 非自己不活化性の発現標的化レトロウイルスベクタ
GR3015892T3 (en) Virus resistant plants having a viral coat protein.
DK0817860T3 (da) Pseudotype retrovirale partikler
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
AU7514087A (en) Vaccine containing the protein f of the aids virus
AU3905893A (en) Plant resistant to two or more viruses and preparation thereof
CA2331440A1 (fr) Lignee cellulaire d'encapsidation de retrovirus amphotropique, procede de production et d'utilisation de ladite lignee
EP0147145A3 (fr) Cellules hôtes de streptomycète à activité de restriction réduite
NZ196835A (en) Total synthesis of irs 4sr 5rs-4-(4,8-dimethyl-5-hydroxy-7-nonenyl)-4-methyl-3,8-dioxabicyclo-(3.2.1)octane-1-acetic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10,DRAWINGS,REPLACED BY NEW PAGES 1/10-10-10;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2092195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991919095

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991919095

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991919095

Country of ref document: EP